The acronym ROADMAP stands for: “Real world Outcomes across the Alzheimer’s Disease spectrum for better care: Multi-modal data Access Platform”.
Phase 1 of ROADMAP began in November 2016 and lasts for two years. October 2017, therefore, marks the halfway point of the project.
In Phase 1 ROADMAP’s goal is to lay the foundation of an EU-wide data sharing space for real-world evidence (RWE) outcomes for better care in Alzheimer's disease.
By the end of October 2018, the ROADMAP consortium, a public private collaboration of 25 partners from Europe, coordinated by the University of Oxford and Novartis, aims to deliver guiding principles and recommendations on integrating available RWE to support healthcare decision making in AD treatment and research.
Successfully delivering therapies to the tens of millions in need will depend on building a sustainable approach that addresses the challenges and opportunities around treatment access at time of approval. In AD this will very much depend on the integration of real-world evidence (RWE) within health care systems to support evidence for approval as well as Health Technology Assessment and funding allocation.
- Project Leader and WorldWide Market Access Director NS at Novartis, Frédéric de Reydet de Vulpillieres
ROADMAP's communications team has created a leaflet for the project partners to use at conferences. The leaflet includes high-level information on the challenges the scientists are aiming to tackle with their work and the leading objectives guiding what they are doing. The aim of the leaflet is to raise awareness about the project and to provide a point of contact for additional database providers, other interested universities, research institutions, and pharmaceutical companies, to further expand ROADMAP's Europe-wide network towards a potential onboarding for a Phase 2.
Download the leaflet from the ROADMAP website.
For more information, visit the ROADMAP website www.roadmap-alzheimer.org and subscribe to the newsletter.
“This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.”